Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort BMJ Online FirstEditorial: Influence of pharmaceutical funding on the conclusions of meta-analyses BMJ Online First
Newswise — Previous work has shown that, when a drug study was funded by the company that made that drug, the results might be biased in favour of that drug because the methods or analyses were manipulated.
New research published on bmj.com today shows that, for blood pressure drugs, studies are now much less likely to have biased results but still tend to have overly positive conclusions favouring the company's products.
The authors call on editors and peer reviewers to scrutinise the conclusions of these studies to ensure that they contain an unbiased interpretation of the results.
Meta-analyses represent the highest level of research evidence in the hierarchy of study types. They pool data from multiple studies to provide summary statistics on the effectiveness of a given treatment. They have a great deal of influence on patient care and healthcare policy and drug companies have started to reference meta-analyses in their advertisements.
Previous studies have shown that randomised controlled trials with financial ties to single drug companies are more likely to have results and conclusions that favour the sponsor's products, and a recent study suggests that the same holds true for meta-analyses.
So researchers in the US set out to determine whether financial ties with single drug companies are associated with favourable results or conclusions in meta-analyses on blood pressure lowering (antihypertensive) therapies.
A total of 124 meta-analyses were included in the study, 49 (40%) of which had single drug company financial ties. Differences in study design and quality were measured.
Meta-analyses with single drug company financial ties were not associated with favourable results but were significantly more likely to have favourable conclusions, even when differences in study quality were taken into account.
In fact, the data show that studies funded by a single drug company have a 55% rate of favourable results that is transformed into a 92% rate for favourable conclusions, representing a 37% gap. The gap shrinks to 21% (57% to 79%) when two or more drug companies provide support. Yet the gap vanishes entirely for studies done by non-profit institutions alone or even in conjunction with drug companies.
These findings suggest a disconnect between the data that underlie the results and the interpretation or "spin" of these data that constitutes the conclusions, say the authors.
The findings also expose a failure of peer review, add the authors, and should act as a wake-up call to editors and peer reviewers, as well as to policy-makers, meta-analysts, and readers. All of these groups should closely scrutinise the conclusions of meta-analyses to ensure that they contain an unbiased interpretation of results, they conclude.
The clear inference from this study is that impartial studies are more reliable, say researchers in an accompanying editorial. However, rather than imposing legal restrictions on drug company funding or participation in these studies, they suggest that doctors should be warned to be cautious in interpreting the conclusions of studies.
Click here to view paper: http://press.psprings.co.uk/bmj/november/financialties.pdfClick here to view editorial: http://press.psprings.co.uk/bmj/november/financialedit.doc
Click here to view full contents for this week's print journal: http://press.psprings.co.uk/bmj/november/contents1711.pdf